ME Live-Signale | Maximieren Sie Profite mit Getagraph.com

KAUFEN 108011 min ago

@ $0.773

Ausgestellt: 14 Feb 2024 @ 21:29

Rendite: -33.24%

Vorheriges Signal: Feb 14 - 16:21

Vorheriges Signal: Verkaufen

Rendite: 3.62 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:00):

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics...

Stats
Tagesvolumen	4.71M
Durchschnittsvolumen	7.57M
Marktkapitalisierung	249.14M
EPS	$0 ( 2024-02-07 )
Nächstes Ertragsdatum	( $-0.150 ) 2024-05-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.460
ATR14	$0.00100 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-18	Hibbs Kathy L	Buy	38 548	Class A Common Stock
2024-04-18	Hibbs Kathy L	Sell	38 548	Class A Common Stock
2024-04-18	Hibbs Kathy L	Sell	38 548	Stock Option (Right to Buy)
2024-04-04	Hibbs Kathy L	Buy	38 548	Class A Common Stock
2024-04-04	Hibbs Kathy L	Sell	38 548	Class A Common Stock

INSIDER POWER
73.77
Last 100 transactions
Buy: 15 283 999 \| Sell: 2 077 892

Volumen Korrelation

Lang: 0.06 (neutral)

Kurz: 0.11 (neutral)

Signal:(50.748) Neutral

23andMe Holding Co. Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

23andMe Holding Co. Korrelation - Währung/Rohstoff

0.00
( neutral )

-0.08
( neutral )

23andMe Holding Co. Finanzdaten

Annual	2022
Umsatz:	$299.49M
Bruttogewinn:	$134.50M (44.91 %)
EPS:	$-0.690

FY	2022
Umsatz:	$299.49M
Bruttogewinn:	$134.50M (44.91 %)
EPS:	$-0.690

FY	2022
Umsatz:	$271.89M
Bruttogewinn:	$132.95M (48.90 %)
EPS:	$-0.600

FY	2021
Umsatz:	$243.92M
Bruttogewinn:	$117.01M (47.97 %)
EPS:	$-0.398

Financial Reports:

No articles found.

23andMe Holding Co.

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.